Title | GC Pharma Reports Full Year 2019 Results | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date of registration | 2020-02-12 | ||||||||||||
Attachment File |
| ||||||||||||
Contents | All consolidated entities revenues grew plus compare to prior year
(1)
Consolidated (2)
Results and percentages compare to the
full financial year 2018 Financial Highlights ● Delivered total revenue growth of 2.6% KRW 1.37 trillion (2018: KRW 1.33 trillion), all consolidated entities revenues grew plus compare to equivalent 2018 period. ● Operating profit decreased 19.7% to KRW 40.3 billion (2018: KRW 41.9 billion), primarily due to an impact of investment in R&D and SG&A. ● One off costs - including corporate tax bill and VAT result in regular tax investigation, evaluation loss of stock investment, impairment losses of tangible asset and penalties from local antitrust regulator related to subsidiary, Green Cross MS, and impairment losses of intangible assets - impacted on after tax profits, expected to progressively ease over the course of 2020. About GC Pharma GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.
# # # |